These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 27058226)

  • 1. Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini.
    Kowalewski DJ; Walz S; Backert L; Schuster H; Kohlbacher O; Weisel K; Rittig SM; Kanz L; Salih HR; Rammensee HG; Stevanović S; Stickel JS
    Blood Cancer J; 2016 Apr; 6(4):e411. PubMed ID: 27058226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Features of TAP-independent MHC class I ligands revealed by quantitative mass spectrometry.
    Weinzierl AO; Rudolf D; Hillen N; Tenzer S; van Endert P; Schild H; Rammensee HG; Stevanović S
    Eur J Immunol; 2008 Jun; 38(6):1503-10. PubMed ID: 18446792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens.
    Backert L; Kowalewski DJ; Walz S; Schuster H; Berlin C; Neidert MC; Schemionek M; Brümmendorf TH; Vucinic V; Niederwieser D; Kanz L; Salih HR; Kohlbacher O; Weisel K; Rammensee HG; Stevanovic S; Walz JS
    Oncotarget; 2017 Jul; 8(27):43915-43924. PubMed ID: 28159928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term immunity against actual poxviral HLA ligands as identified by differential stable isotope labeling.
    Meyer VS; Kastenmuller W; Gasteiger G; Franz-Wachtel M; Lamkemeyer T; Rammensee HG; Stevanovic S; Sigurdardottir D; Drexler I
    J Immunol; 2008 Nov; 181(9):6371-83. PubMed ID: 18941228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficiency and mechanism of antigen-specific CD8+ T-cell activation using synthetic long peptides.
    Zandvliet ML; Kester MG; van Liempt E; de Ru AH; van Veelen PA; Griffioen M; Guchelaar HJ; Falkenburg JH; Meij P
    J Immunother; 2012; 35(2):142-53. PubMed ID: 22306902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy.
    Walz S; Stickel JS; Kowalewski DJ; Schuster H; Weisel K; Backert L; Kahn S; Nelde A; Stroh T; Handel M; Kohlbacher O; Kanz L; Salih HR; Rammensee HG; Stevanović S
    Blood; 2015 Sep; 126(10):1203-13. PubMed ID: 26138685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation.
    Bassani-Sternberg M; Pletscher-Frankild S; Jensen LJ; Mann M
    Mol Cell Proteomics; 2015 Mar; 14(3):658-73. PubMed ID: 25576301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I.
    Yang G; Gao M; Zhang Y; Kong Y; Gao L; Tao Y; Han Y; Wu H; Meng X; Xu H; Zhan F; Wu X; Shi J
    Oncotarget; 2015 Sep; 6(29):26982-94. PubMed ID: 26323098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands on myeloid leukemia cells by TCR-transgenic T cells.
    Klar R; Schober S; Rami M; Mall S; Merl J; Hauck SM; Ueffing M; Admon A; Slotta-Huspenina J; Schwaiger M; Stevanović S; Oostendorp RA; Busch DH; Peschel C; Krackhardt AM
    Leukemia; 2014 Dec; 28(12):2355-66. PubMed ID: 24736212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome-inhibited dendritic cells demonstrate improved presentation of exogenous synthetic and natural HLA-class I peptide epitopes.
    Chromik J; Schnürer E; Georg Meyer R; Wehler T; Tüting T; Wölfel T; Huber C; Herr W
    J Immunol Methods; 2006 Jan; 308(1-2):77-89. PubMed ID: 16336973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biogenesis of HLA Ligand Presentation in Immune Cells Upon Activation Reveals Changes in Peptide Length Preference.
    Marino F; Semilietof A; Michaux J; Pak HS; Coukos G; Müller M; Bassani-Sternberg M
    Front Immunol; 2020; 11():1981. PubMed ID: 32983136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes.
    Gloger A; Ritz D; Fugmann T; Neri D
    Cancer Immunol Immunother; 2016 Nov; 65(11):1377-1393. PubMed ID: 27600516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tripeptidyl peptidase II is dispensable for the generation of both proteasome-dependent and proteasome-independent ligands of HLA-B27 and other class I molecules.
    Marcilla M; Villasevil EM; de Castro JA
    Eur J Immunol; 2008 Mar; 38(3):631-9. PubMed ID: 18286573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
    Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
    Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors.
    Gavioli R; Vertuani S; Masucci MG
    Int J Cancer; 2002 Oct; 101(6):532-8. PubMed ID: 12237893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A large fraction of HLA class I ligands are proteasome-generated spliced peptides.
    Liepe J; Marino F; Sidney J; Jeko A; Bunting DE; Sette A; Kloetzel PM; Stumpf MP; Heck AJ; Mishto M
    Science; 2016 Oct; 354(6310):354-358. PubMed ID: 27846572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell Surface MHC Class I Expression Is Limited by the Availability of Peptide-Receptive "Empty" Molecules Rather than by the Supply of Peptide Ligands.
    Komov L; Kadosh DM; Barnea E; Milner E; Hendler A; Admon A
    Proteomics; 2018 Jun; 18(12):e1700248. PubMed ID: 29707912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of HLA-E with peptides and the peptide transporter in vitro: implications for its function in antigen presentation.
    Ulbrecht M; Modrow S; Srivastava R; Peterson PA; Weiss EH
    J Immunol; 1998 May; 160(9):4375-85. PubMed ID: 9574542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
    Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
    J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and characterization of HIV-1 epitopes presented by HLA-A*2603: comparison between HIV-1 epitopes presented by A*2601 and A*2603.
    Kawashima Y; Satoh M; Oka S; Takiguchi M
    Hum Immunol; 2005 Nov; 66(11):1155-66. PubMed ID: 16571416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.